

Prof. Janja Ocvirk was born in Ljubljana 1966. She finished Faculty of Medicine , University of Ljubljana, she pass Master's degree and Doctor's degree. She is Medical Oncologist at the Institute of Oncology Ljubljana and Professor in Oncology at the Faculty of Medicine, University of Ljubljana (Slovenia). She is Consultant in Medical Oncology, Head of Melanoma Multidisciplinary Team, Head of Department for medical oncology at the Institute of Oncology Ljubljana. She is principal investigator of many international clinical trials in colorectal cancer, gastric cancer, melanoma, non-melanoma skin cancers and principal investigator/co-investigator of more than 10 investigator initiated studies. She published more than 100 scientific papers, some book chapters.

CV – Prof. Dr. Janja Ocvirk

Name: Janja Ocvirk, MD, PhD, Assoc. professor in Oncology
Date of birth: 30.10.1966

Academic Career:

1992 - 1994: Junior research Fellow, Institute of Oncology Ljubljana
1994 - 1997: Resident in internal medicine, Institute of Oncology Ljubljana
1995: Master's degree (MSc) at Faculty of Medicine, University of Ljubljana
1997: Specialist in internal medicine
2000: Doctor's degree (PhD) at Faculty of Medicine, University of Ljubljana
2002: Consultant in Medical Oncology
2010: Professor in Oncology

Licensed for internal medicine and medical oncology

Current position: Head of Melanoma Multidisciplinary Team, Head of Department for medical oncology at the Institute of Oncology Ljubljana

Main domain of research:

Clinical research in melanoma, BCC and gastrointestinal cancers.

Publications:

50 original scientific papers, 2 review articles; 2 book chapters, 1 patent

10 most recent publications:

1. Tanja Mesti, Maja Ebert Moltara, Marko Boc, Martina Reberšek, Janja Ocvirk, "Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience", *Radiol. oncol. (Ljubl.)*, vol. 49, no. 1, str. 80-85, VI, Mar. 2015, doi: [10.2478/raon-2014-0021](https://doi.org/10.2478/raon-2014-0021). [COBISS.SI-ID [1813371](https://www.cobiss.si/id/1813371)]
2. Tanja Mesti, Biljana Mileva-Boshkoska, Mitja Kos, Metka Tekavčič, Janja Ocvirk, "The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia : discrepancy analysis between cost and reimbursement", *Radiol. oncol. (Ljubl.)*, vol. 49, iss. 2, str. 200-

208, Jun. 2015, doi: [10.2478/raon-2014-0046](https://doi.org/10.2478/raon-2014-0046). [COBISS.SI-ID [1944187](#)]

3. Tanja Mesti, Philippe Savarin, Mohamed N. Triba, Laurence Le Moyec, Janja Ocvirk, Claire Banissi, Antoine F. Carpentier, "Metabolic impact of anti-angiogenic agents on U87 glioma cells", *PloS one*, vol. 9, iss. 6, Jun. 2014,

<http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099198>, doi:

[10.1371/journal.pone.0099198](https://doi.org/10.1371/journal.pone.0099198). [COBISS.SI-ID [1813627](#)]

4. David Cunningham, Istvan Lang, Eugenio Marcuello, Vito Lorusso, Janja Ocvirk, Dong Bok Shin, Derek J. Jonker, Stuart Osborne, Niko Alexander Andre, Daniel Waterkamp, Mark Saunders, "Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX) : an open-label, randomised phase 3 trial", *Lancet oncol. (Print)*, vol. 14, iss. 11, str. 1077-1085, Oct. 2013, http://ac.els-cdn.com/S1470204513701542/1-s2.0-S1470204513701542-main.pdf?_tid=920abea8-452c-11e3-8b12-0000aacb35e&acdnat=1383554528_8df15f5c3061d1ddd8455cdd6686091, doi:

[10.1016/S1470-2045\(13\)70154-2](https://doi.org/10.1016/S1470-2045(13)70154-2). [COBISS.SI-ID [1632123](#)]

5. Irena Oblak, Vaneja Velenik, Franc Anderluh, Barbara Možina, Janja Ocvirk, "The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer", *Radiol. oncol. (Ljubl.)*, vol. 47, no. 2, str. 138-144, IV, jun. 2013, doi: [10.2478/raon-2013-0028](https://doi.org/10.2478/raon-2013-0028). [COBISS.SI-ID [1507963](#)]

6. Janja Ocvirk, Steffen Heeger, Philip McCloud, Ralf-Dieter Hofheinz, "A review of the treatment options for skin rash induced by EGFR-targeted therapies : evidence from randomized clinical trials and a meta-analysis", *Radiol. oncol. (Ljubl.)*, vol. 47, no. 2, str. 166-175, VI, jun. 2013, doi: [10.2478/raon-2013-0014](https://doi.org/10.2478/raon-2013-0014). [COBISS.SI-ID [1577851](#)]

7. Janja Ocvirk, Martina Reberšek, Erik Škof, Zvezdana Hlebanja, Marko Boc, "Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer", *Am. j. clin. oncol.*, vol. 35, no. 3, str. 237-241, 2012, doi: [10.1097/COC.0b013e31820dc0b0](https://doi.org/10.1097/COC.0b013e31820dc0b0). [COBISS.SI-ID [1215099](#)]

8. Dominik P. Modest, Thomas Brodowicz, Sebastian Stintzing, Andreas Jung, Jens Neumann, R. P. Laubender, Janja Ocvirk, G. Kurteva, Z. Papai, R. Knittelfelder, Thomas Kirchner, V. Heinemann, Christoph C. Zielinski, "Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy : a pooled analysis of three trials", *Oncology*, vol. 83, no. 5, str. 241-247, 2012, doi: [10.1159/000339534](https://doi.org/10.1159/000339534). [COBISS.SI-ID [1454715](#)]

9. Vaneja Velenik, Janja Ocvirk, Irena Oblak, Franc Anderluh, "Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial", *Radiol. oncol. (Ljubl.)*, vol. 46, no. 3, str. 252-257, V, 2012, doi: [10.2478/v10019-012-0030-2](https://doi.org/10.2478/v10019-012-0030-2). [COBISS.SI-ID [1362299](#)]

10. Janja Ocvirk, Martina Reberšek, Marko Boc, "Bevacizumab in first-line therapy of metastatic colorectal cancer : a retrospective comparison of FOLFIRI and XELIRI", *Anticancer res.*, vol. 31, no. 5, str. 1777-1782, 2011. [COBISS.SI-ID [1099899](#)]

Patent:

Čurin-Šerbec V, Schuurbijs A, Menart V, Gaberc-Porekar V, Štavec A, Žunc P, **Ocvirk J**, Štabuc B. Monoclonal antibodies against soluble TGF- α receptors p55 and p75 well as against TNF α and its analogues : patent : EP 0846169 (BI), 2003-03-19. Munchen : European Patent Office, 2003.